Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aastrom Biosciences Issues Correction of Wall Street Journal Article
-- Adult Bone Marrow Stem Cells are Company Focus --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2005 Financial Results
Aastrom Biosciences, Inc. Reports First Quarter Fiscal Year 2005 Financial Results Ann Arbor, Michigan, November 4 , 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today reported financial results for the first fiscal quarter ended September 30, 2004.  The Company also reported several
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call Tomorrow
Aastrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, November 3, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call tomorrow, Thursday, November 4, 2004 at 11:00 a.m. (EST).
View HTML
Toggle Summary Webcast Alert: Aastrom Biosciences, Inc. Presentation At Informed Investors
Biotechnology/Cancer Stocks Virtual Forum To Be Webcast On Thursday, November 4, 2004, 9:30am ET
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, November 1, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will host an investor conference call on Thursday, November 4, 2004 at 11:00 a.m. (EST). The call will begin with brief presentations by
View HTML
Toggle Summary Aastrom Biosciences Announces Diabetic Limb Ischemia Clinical Trial Agreement
-- Aastrom's Proprietary TRCs to be Used in Treatment of Limb Ischemia at the Bad Oeynhausen Heart and Diabetes Center in Germany --
View HTML
Toggle Summary Aastrom Biosciences Raises $10 Million in Equity Financing
Aastrom Biosciences Raises $10 Million in Equity Financing Ann Arbor, Michigan, October 27, 2004 - Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has executed definitive Stock Purchase Agreements for the sale of approximately 8.26 million shares of the Company's common stock in
View HTML
Toggle Summary Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
Aastrom Biosciences CEO to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference Ann Arbor, Michigan, October 25, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today R. Douglas Armstrong, Ph.D., Chairman and Chief Executive Officer, will present at the Rodman &
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Clinical Trial for Sinus Lift Bone Graft Procedures in Spain
-- Aastrom's Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants --
View HTML
Toggle Summary Aastrom Biosciences Announces Initiation of Clinical Trial for Sinus Lift Bone Graft Procedures in Spain
-- Aastrom's Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants --
View HTML

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.